Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

Exclusion Criteria

• •Current AIDS-defining illness
• •Virologic failure (HIV RNA \> 10,000 copies/ml) while receiving current HAART regimen
• •Immunomodulating agents, including interleukins; antibodies reactive with lymphocytes, monocytes, or antigen presenting cells; and polyribonucleotides
• •IL-2 therapy within 4 weeks of study entry
• •Uncontrolled active cardiac, renal, pulmonary, hepatic, or CNS disease
• •History of active malignancy requiring chemotherapy
• •History of thyroid disease or autoimmune disorders, including asthma, inflammatory bowel disease, rheumatoid arthritis, and psoriasis
• •Active infection with hepatitis B virus or hepatitis C virus
• •Severe retinopathy due to diabetes, hypertension, CMV, or macular degeneration
• •Serious infection or other serious medical illness that is potentially life threatening and requires systemic therapy and/or hospitalization within 14 days of study entry
• •Substance abuse that will compromise the participant's ability to adhere to the study requirements
• •Current alcohol use of more than 1 drink/day any time during 6 months prior to study entry. One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.25 ounces of hard liquor.
• •History of allergy to eggs, IL-2, or other components of the vaccine or IL-2 formulation
• •Pregnant or breast-feeding
• •Professionals working in close contact with canaries (e.g., breeding farms, bird shops)